Menu

Biocartis launches innovative Idylla™ MSI Assay

Idylla™ MSI Assay further strengthens Biocartis’ test menu and offers opportunities to enter the immuno-oncology testing market
Non-regulated information

Study Reviewing 2,500 Performed Idylla™ Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods

Non-regulated information

Study Demonstrates Ability of Idylla™ EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests

Non-regulated information

Two Performance Studies on Idylla™ MSI Biomarkers Selected for Publication at ASCO Conference

Non-regulated information

Biocartis Abstract on Performance Idylla™ ctRAS Liquid Biopsy Tests Selected for Oral Presentation at 2018 American Association for Cancer Research Meeting

Non-regulated information

Biocartis Establishes R&D Center in the US

Biocartis team strengthened with joining of the Janssen Idylla™ assay development team
Non-regulated information

Biocartis & Immunexpress Sign Partnership for a Sepsis Host Immune Response Test on the Idylla™ platform

Non-regulated information

Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology Compound

Non-regulated information

Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla™ RAS Biomarker Tests

Agreement aims to deliver faster biomarker results to realize more informed treatment decisions
Non-regulated information

Biocartis launches CE-marked IVD RAS liquid biopsy tests developed under partnership with Merck KGaA, Darmstadt, Germany

The Idylla™ ctRAS liquid biopsy tests detect RAS mutations in patients with metastatic colorectal cancer
Non-regulated information